studies

metastatic/adv melanoma (mML), pembrolizumab (10mg/kg) vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.74 [0.57; 0.96] KEYNOTE-006 (3 week), 2015 0.69 [0.52; 0.91] 0.72[0.59; 0.86]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%915moderatenot evaluable deaths (OS) (extension)detailed resultsKEYNOTE-006 (3 week), 2015 0.68 [0.53; 0.87] 0.68[0.53; 0.87]KEYNOTE-006 (3 week), 201510%555NAnot evaluable PFS (extension)detailed resultsKEYNOTE-006 (3 week), 2015 0.61 [0.50; 0.75] 0.61[0.50; 0.75]KEYNOTE-006 (3 week), 201510%555NAnot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.50 [0.39; 0.64] KEYNOTE-006 (3 week), 2015 0.58 [0.47; 0.72] 0.54[0.46; 0.64]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%915moderatenot evaluable objective responses (ORR)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 8.16 [3.74; 17.80] KEYNOTE-006 (3 week), 2015 3.63 [2.34; 5.65] 5.09[2.33; 11.13]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015268%915moderatenot evaluable STRAE (any grade)detailed resultsKEYNOTE-006 (3 week), 2015 0.63 [0.39; 1.03] 0.63[0.39; 1.03]KEYNOTE-006 (3 week), 201510%533NAnot evaluable STRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.92[0.02; 46.74]KEYNOTE-006 (3 week), 201510%533NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.76 [0.45; 1.26] KEYNOTE-006 (3 week), 2015 1.16 [0.78; 1.72] 0.97[0.64; 1.46]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015240%883moderatenot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.54 [0.32; 0.91] KEYNOTE-006 (3 week), 2015 0.82 [0.53; 1.28] 0.68[0.46; 1.02]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015229%883moderatenot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 1.40[0.11; 18.31]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.65 [0.70; 3.87] KEYNOTE-006 (3 week), 2015 1.23 [0.69; 2.18] 1.35[0.84; 2.17]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 2.73 [0.85; 8.76] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 2.50[0.82; 7.64]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.92[0.02; 46.74]KEYNOTE-006 (3 week), 201510%533NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.94[0.06; 15.07]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.05 [0.00; 0.88] KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80] 0.13[0.01; 1.12]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.94[0.10; 9.13]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.06; 15.39] KEYNOTE-006 (3 week), 2015 0.23 [0.01; 5.12] 0.51[0.06; 4.02]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Chills TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.92[0.02; 46.74]KEYNOTE-006 (3 week), 201510%533NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 2.90 [0.30; 28.13] KEYNOTE-006 (3 week), 2015 0.34 [0.14; 0.83] 0.76[0.10; 5.79]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015266%883moderatenot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.94[0.06; 15.07]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Cough TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.92[0.02; 46.74]KEYNOTE-006 (3 week), 201510%533NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.94[0.06; 15.07]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 1.85 [0.06; 55.43] 1.85[0.06; 55.43]KEYNOTE-006 (3 week), 201510%533NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.28 [0.28; 5.81] KEYNOTE-006 (3 week), 2015 0.39 [0.10; 1.52] 0.67[0.21; 2.15]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015224%883moderatenot evaluable Dry skin TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.94[0.06; 15.07]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85] 0.92[0.06; 14.85]KEYNOTE-006 (3 week), 201510%533NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.05; 1.10] KEYNOTE-006 (3 week), 2015 0.92 [0.18; 4.62] 0.45[0.12; 1.77]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 2015232%883moderatenot evaluable Headache TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.92[0.02; 46.74]KEYNOTE-006 (3 week), 201510%533NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 3.85 [0.17; 86.06] KEYNOTE-006 (3 week), 2015 4.69 [0.54; 40.40] 4.40[0.75; 25.82]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80] 0.63[0.05; 8.23]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11] 0.56[0.07; 4.37]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.94[0.06; 15.07]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11] 0.46[0.04; 5.11]KEYNOTE-006 (3 week), 201510%533NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11] 0.46[0.04; 5.11]KEYNOTE-006 (3 week), 201510%533NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.07 [0.00; 1.17] 0.07[0.00; 1.17]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85] 1.24[0.14; 10.63]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.48 [0.02; 14.29] KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80] 0.47[0.04; 5.19]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.92[0.02; 46.74]KEYNOTE-006 (3 week), 201510%533NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.33[0.05; 2.22]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80] 0.46[0.02; 13.80]KEYNOTE-006 (3 week), 201510%533NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.08 [0.00; 1.39] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.18[0.02; 1.90]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] 1.92[0.06; 57.48]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Paraesthesia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80] 0.63[0.05; 8.23]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Peripheral neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.24 [0.01; 5.29] 0.24[0.01; 5.29]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 5.81 [0.29; 116.90] KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85] 2.16[0.28; 16.57]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Pruritic rash TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.92[0.02; 46.74]KEYNOTE-006 (3 week), 201510%533NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.94[0.06; 15.07]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.92[0.02; 46.74]KEYNOTE-006 (3 week), 201510%533NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.94[0.06; 15.07]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12] 0.23[0.03; 2.12]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Uveitis TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 1.92 [0.06; 57.48] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 1.40[0.11; 18.31]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Vitiligo TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.96 [0.02; 48.41] 0.96[0.02; 48.41]KEYNOTE-002 (10 mg/kg), 201510%350NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-002 (10 mg/kg), 2015 0.23 [0.03; 2.12] KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74] 0.33[0.05; 2.22]KEYNOTE-002 (10 mg/kg), 2015, KEYNOTE-006 (3 week), 201520%883moderatenot evaluable Weight decreased TRAE (grade 3-4)detailed resultsKEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80] 0.46[0.02; 13.80]KEYNOTE-006 (3 week), 201510%533NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-01 18:27 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 283,284,70,235,285,68,127,128,286,69,129 - treatments: 575

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons